Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy - Induced increases in CD4+ cell count: A randomized, double-blind, placebo-controlled trial

J. S. Currier, P. L. Williams, S. L. Koletar, S. E. Cohn, R. L. Murphy, A. E. Heald, R. Hafner, E. L. Bassily, Howard M Lederman, C. Knirsch, C. A. Benson, H. Valdez, J. A. Aberg, J. A. McCutchan

Research output: Contribution to journalArticle

Abstract

Background: Patients infected with HIV who experience increases in CD4+ cell counts are at reduced risk for opportunistic infections. However, the safety of discontinuing prophylaxis against Mycobacterium avium complex has been uncertain. Objective: To compare the rate of M. avium complex infection in patients with increased CD4+ cell counts who receive azithromycin and those receiving placebo. Design: Randomized, double-blind, placebo-controlled trial. Setting: 29 university-based clinical centers in the United States. Participants: 643 HIV-1-infected patients with a previous CD4+ cell count less than 0.05 x 109 cells/L and a sustained increase to greater than 0.10 x 109 cells/L during antiretroviral therapy. Intervention: Azithromycin, 1200 mg once weekly (n = 321), or matching placebo (n = 322). Measurements: Mycobacterium avium complex cultures, CD4+ cell counts, and clinical evaluations for AIDS-defining illnesses and bacterial infections were done every 8 weeks. Plasma HIV-1 RNA levels were measured at 16-week intervals. Results: During follow-up (median, 16 months), 2 cases of M. avium complex infection were reported among the 321 patients assigned to placebo (incidence rate, 0.5 event per 100 personyears [95% Cl, 0.06 to 1.83 events per 100 person-years]) compared with no cases among the 322 patients assigned to azithromycin (Cl, 0 to 0.92 events per 100 person-years), resulting in a treatment difference of 0.5 event per 100 person-years (Cl, -0.20 to 1.21 events per 100 person-years) for placebo versus azithromycin. Both cases were atypical in that M. avium complex was localized to the vertebral spine. Patients receiving azithromycin were more likely than those receiving placebo to discontinue treatment with the study drug permanently because of adverse events (8% vs. 2%; hazard ratio, 0.24 [Cl, 0.10 to 0.57]). Conclusions: Prophylaxis against Mycobacterium avium complex can safely be withdrawn or withheld in adults with HIV infection who experience increases in CD4+ cell count while receiving antiretroviral therapy.

Original languageEnglish (US)
Pages (from-to)493-503
Number of pages11
JournalAnnals of Internal Medicine
Volume133
Issue number7
StatePublished - Oct 3 2000
Externally publishedYes

Fingerprint

Mycobacterium avium Complex
CD4 Lymphocyte Count
Azithromycin
Placebos
HIV-1
Therapeutics
Opportunistic Infections
Infection
Bacterial Infections
HIV Infections
Acquired Immunodeficiency Syndrome
Spine
HIV
RNA
Safety
Incidence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy - Induced increases in CD4+ cell count : A randomized, double-blind, placebo-controlled trial. / Currier, J. S.; Williams, P. L.; Koletar, S. L.; Cohn, S. E.; Murphy, R. L.; Heald, A. E.; Hafner, R.; Bassily, E. L.; Lederman, Howard M; Knirsch, C.; Benson, C. A.; Valdez, H.; Aberg, J. A.; McCutchan, J. A.

In: Annals of Internal Medicine, Vol. 133, No. 7, 03.10.2000, p. 493-503.

Research output: Contribution to journalArticle

Currier, JS, Williams, PL, Koletar, SL, Cohn, SE, Murphy, RL, Heald, AE, Hafner, R, Bassily, EL, Lederman, HM, Knirsch, C, Benson, CA, Valdez, H, Aberg, JA & McCutchan, JA 2000, 'Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy - Induced increases in CD4+ cell count: A randomized, double-blind, placebo-controlled trial', Annals of Internal Medicine, vol. 133, no. 7, pp. 493-503.
Currier, J. S. ; Williams, P. L. ; Koletar, S. L. ; Cohn, S. E. ; Murphy, R. L. ; Heald, A. E. ; Hafner, R. ; Bassily, E. L. ; Lederman, Howard M ; Knirsch, C. ; Benson, C. A. ; Valdez, H. ; Aberg, J. A. ; McCutchan, J. A. / Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy - Induced increases in CD4+ cell count : A randomized, double-blind, placebo-controlled trial. In: Annals of Internal Medicine. 2000 ; Vol. 133, No. 7. pp. 493-503.
@article{6867ddead93648d395a6e4af767b5f1f,
title = "Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy - Induced increases in CD4+ cell count: A randomized, double-blind, placebo-controlled trial",
abstract = "Background: Patients infected with HIV who experience increases in CD4+ cell counts are at reduced risk for opportunistic infections. However, the safety of discontinuing prophylaxis against Mycobacterium avium complex has been uncertain. Objective: To compare the rate of M. avium complex infection in patients with increased CD4+ cell counts who receive azithromycin and those receiving placebo. Design: Randomized, double-blind, placebo-controlled trial. Setting: 29 university-based clinical centers in the United States. Participants: 643 HIV-1-infected patients with a previous CD4+ cell count less than 0.05 x 109 cells/L and a sustained increase to greater than 0.10 x 109 cells/L during antiretroviral therapy. Intervention: Azithromycin, 1200 mg once weekly (n = 321), or matching placebo (n = 322). Measurements: Mycobacterium avium complex cultures, CD4+ cell counts, and clinical evaluations for AIDS-defining illnesses and bacterial infections were done every 8 weeks. Plasma HIV-1 RNA levels were measured at 16-week intervals. Results: During follow-up (median, 16 months), 2 cases of M. avium complex infection were reported among the 321 patients assigned to placebo (incidence rate, 0.5 event per 100 personyears [95{\%} Cl, 0.06 to 1.83 events per 100 person-years]) compared with no cases among the 322 patients assigned to azithromycin (Cl, 0 to 0.92 events per 100 person-years), resulting in a treatment difference of 0.5 event per 100 person-years (Cl, -0.20 to 1.21 events per 100 person-years) for placebo versus azithromycin. Both cases were atypical in that M. avium complex was localized to the vertebral spine. Patients receiving azithromycin were more likely than those receiving placebo to discontinue treatment with the study drug permanently because of adverse events (8{\%} vs. 2{\%}; hazard ratio, 0.24 [Cl, 0.10 to 0.57]). Conclusions: Prophylaxis against Mycobacterium avium complex can safely be withdrawn or withheld in adults with HIV infection who experience increases in CD4+ cell count while receiving antiretroviral therapy.",
author = "Currier, {J. S.} and Williams, {P. L.} and Koletar, {S. L.} and Cohn, {S. E.} and Murphy, {R. L.} and Heald, {A. E.} and R. Hafner and Bassily, {E. L.} and Lederman, {Howard M} and C. Knirsch and Benson, {C. A.} and H. Valdez and Aberg, {J. A.} and McCutchan, {J. A.}",
year = "2000",
month = "10",
day = "3",
language = "English (US)",
volume = "133",
pages = "493--503",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "7",

}

TY - JOUR

T1 - Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy - Induced increases in CD4+ cell count

T2 - A randomized, double-blind, placebo-controlled trial

AU - Currier, J. S.

AU - Williams, P. L.

AU - Koletar, S. L.

AU - Cohn, S. E.

AU - Murphy, R. L.

AU - Heald, A. E.

AU - Hafner, R.

AU - Bassily, E. L.

AU - Lederman, Howard M

AU - Knirsch, C.

AU - Benson, C. A.

AU - Valdez, H.

AU - Aberg, J. A.

AU - McCutchan, J. A.

PY - 2000/10/3

Y1 - 2000/10/3

N2 - Background: Patients infected with HIV who experience increases in CD4+ cell counts are at reduced risk for opportunistic infections. However, the safety of discontinuing prophylaxis against Mycobacterium avium complex has been uncertain. Objective: To compare the rate of M. avium complex infection in patients with increased CD4+ cell counts who receive azithromycin and those receiving placebo. Design: Randomized, double-blind, placebo-controlled trial. Setting: 29 university-based clinical centers in the United States. Participants: 643 HIV-1-infected patients with a previous CD4+ cell count less than 0.05 x 109 cells/L and a sustained increase to greater than 0.10 x 109 cells/L during antiretroviral therapy. Intervention: Azithromycin, 1200 mg once weekly (n = 321), or matching placebo (n = 322). Measurements: Mycobacterium avium complex cultures, CD4+ cell counts, and clinical evaluations for AIDS-defining illnesses and bacterial infections were done every 8 weeks. Plasma HIV-1 RNA levels were measured at 16-week intervals. Results: During follow-up (median, 16 months), 2 cases of M. avium complex infection were reported among the 321 patients assigned to placebo (incidence rate, 0.5 event per 100 personyears [95% Cl, 0.06 to 1.83 events per 100 person-years]) compared with no cases among the 322 patients assigned to azithromycin (Cl, 0 to 0.92 events per 100 person-years), resulting in a treatment difference of 0.5 event per 100 person-years (Cl, -0.20 to 1.21 events per 100 person-years) for placebo versus azithromycin. Both cases were atypical in that M. avium complex was localized to the vertebral spine. Patients receiving azithromycin were more likely than those receiving placebo to discontinue treatment with the study drug permanently because of adverse events (8% vs. 2%; hazard ratio, 0.24 [Cl, 0.10 to 0.57]). Conclusions: Prophylaxis against Mycobacterium avium complex can safely be withdrawn or withheld in adults with HIV infection who experience increases in CD4+ cell count while receiving antiretroviral therapy.

AB - Background: Patients infected with HIV who experience increases in CD4+ cell counts are at reduced risk for opportunistic infections. However, the safety of discontinuing prophylaxis against Mycobacterium avium complex has been uncertain. Objective: To compare the rate of M. avium complex infection in patients with increased CD4+ cell counts who receive azithromycin and those receiving placebo. Design: Randomized, double-blind, placebo-controlled trial. Setting: 29 university-based clinical centers in the United States. Participants: 643 HIV-1-infected patients with a previous CD4+ cell count less than 0.05 x 109 cells/L and a sustained increase to greater than 0.10 x 109 cells/L during antiretroviral therapy. Intervention: Azithromycin, 1200 mg once weekly (n = 321), or matching placebo (n = 322). Measurements: Mycobacterium avium complex cultures, CD4+ cell counts, and clinical evaluations for AIDS-defining illnesses and bacterial infections were done every 8 weeks. Plasma HIV-1 RNA levels were measured at 16-week intervals. Results: During follow-up (median, 16 months), 2 cases of M. avium complex infection were reported among the 321 patients assigned to placebo (incidence rate, 0.5 event per 100 personyears [95% Cl, 0.06 to 1.83 events per 100 person-years]) compared with no cases among the 322 patients assigned to azithromycin (Cl, 0 to 0.92 events per 100 person-years), resulting in a treatment difference of 0.5 event per 100 person-years (Cl, -0.20 to 1.21 events per 100 person-years) for placebo versus azithromycin. Both cases were atypical in that M. avium complex was localized to the vertebral spine. Patients receiving azithromycin were more likely than those receiving placebo to discontinue treatment with the study drug permanently because of adverse events (8% vs. 2%; hazard ratio, 0.24 [Cl, 0.10 to 0.57]). Conclusions: Prophylaxis against Mycobacterium avium complex can safely be withdrawn or withheld in adults with HIV infection who experience increases in CD4+ cell count while receiving antiretroviral therapy.

UR - http://www.scopus.com/inward/record.url?scp=0034601814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034601814&partnerID=8YFLogxK

M3 - Article

C2 - 11015162

AN - SCOPUS:0034601814

VL - 133

SP - 493

EP - 503

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 7

ER -